Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Afatinib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11 Gastrointestinal 2 Thoracic 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Glioblastoma 3 Brain Neoplasms 2 Recurrence 1 Oligodendroglioma 1 Meningioma 1 Meningeal Carcinomatosis 1 Lung Neoplasms 1 Breast Neoplasms 1 Astrocytoma 1

Interventions

Trastuzumab 17 Radiosurgery 14 Magnetic Resonance Spectroscopy 14 Capecitabine 13 Radiotherapy 11 Lapatinib 10 Specimen Handling 9 trastuzumab deruxtecan 8 Temozolomide 8 Cyclophosphamide 8 Docetaxel 7 Paclitaxel 6 Cisplatin 6 Therapeutics 5 Spinal Puncture 5 Gemcitabine 5 Flow Cytometry 5 tucatinib 4 sacituzumab govitecan 4 pembrolizumab 4 paclitaxel-Angiopep-2 conjugate 4 eribulin 4 Vinorelbine 4 Methotrexate 4 Fluorodeoxyglucose F18 4 Dexamethasone 4 Bevacizumab 4 temsirolimus 3 pyrotinib 3 fludarabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02768337 2024-01-31

CamBMT1

Cambridge University Hospitals NHS Foundation Trust

Phase 1/2 Terminated

BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡